Shares of ReNeuron Group Plc (LON: RENE) today surged 10.2% after the company announced that it had started extended phase IIa trials of its hRPC cell therapy for retinitis pigmentosa, a degenerative eye condition.
The company which specialises in stem-cell research today announced that it had started dosing procedures within the US and that the expanded phase IIa trial will include at least nine people who will receive higher doses of the hRPC cell therapy.
Ten patients are already participating in the study, which will raise the total number to nineteen patients, distributed across the UK and America. Further results will be published in the next 12 months.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The hRPC treatment has been granted orphan drug status in both the US and Europe with the US Food & Drug Administration (FDA) giving it fast-track status, which bodes well for the treatment.
ReNeuron share price
ReNeuron shares today surged 10.2% to trade at 99p having ended Wednesday’s session trading at 89.8p.
People who read this also read:
